Correction to Sonoma Biotherapeutics Headlines
March 28 2023 - 7:25AM
Dow Jones News
Sonoma Biotherapeutics is a clinical-stage biotechnology company
developing engineered regulatory T cell therapies. "Sonoma
Biotherapeutics, Regeneron Announce Collaboration to Discover,
Develop and Commercialize Treg Cell Therapies for Autoimmune
Diseases," published at 7:30 a.m. ET, and a subsequent headline
incorrectly included the ticker code SNOA for Sonoma
Pharmaceuticals Inc.
(END) Dow Jones Newswires
March 28, 2023 08:10 ET (12:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2024 to May 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2023 to May 2024